A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients
Status:
Completed
Trial end date:
2024-04-10
Target enrollment:
Participant gender:
Summary
This study will enroll individuals who have end stage renal disease and who are undergoing a
solitary kidney transplant. This study is investigating/evaluating the safety and
effectiveness of collecting, expanding and infusing a specific certain type of immune cell
known as Regulatory T cells (Treg cells) to renal transplant recipients who are using
Zortress (Everolimus) as immunosuppressive therapy.
Treg cells, once they have been expanded in the laboratory to help prevent kidney rejection.
Treg cells are collected from a participant's blood through a procedure called apheresis.
Treg cells are a type of white blood cells that are able to suppress the activity of other
immune cells responsible for organ rejection. The investigator plans to enroll 12
participants at the University of Kentucky.